We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Eli Lilly’s profit doubled in the fourth quarter ... Revenue from the breast cancer treatment Verzenio also helped in the fourth quarter, climbing 36% to $1.55 billion. Overall, Lilly’s ...

30-Day Overview Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance ...

Eli Lilly's profit doubled in the fourth quarter ... Revenue from the breast cancer treatment Verzenio also helped in the fourth quarter, climbing 36 percent to $1.55 billion.